Skip to main content
. Author manuscript; available in PMC: 2015 Jan 23.
Published in final edited form as: Trends Mol Med. 2005 Aug;11(8):344–347. doi: 10.1016/j.molmed.2005.06.010

Figure 1.

Figure 1

Visfatin (PBEF) action. (a) In the lean state, visfatin production is low and its action on insulin sensitivity might be negligible. (b) Intra-abdominal obesity leads to increased visfatin production, which might simultaneously increase obesity and maintain insulin sensitivity in peripheral organs.